Current clinical management of gastrointestinal stromal tumors

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 595-605

  Tosoni, Alicia ^a   Nicolardi, Linda ^a   Brandes, Alba A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Gastrointestinal stromal tumor; Imatinib; Review; Therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STEM CELL FACTOR RECEPTOR;

CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; METASTASIS POTENTIAL; MYALGIA; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PREVALENCE; REVIEW; VOMITING;

EID: 4444316080     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.595     Document Type: Review

References (85)

1. Miettinem M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch. 438, 1-12 (2001).
2. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J. Pathol. 202, 430-438 (2004).
3. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab. Invest. 84, 874-883 (2004).
4. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J. Surg. Pathol. 28, 889-894 (2004).
5. Blay P, Astudillo A, Buesa JM et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin. Cancer Res. 10, 4089-4095 (2004).
6. West RB, Corless CL, Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 165, 107-113 (2004).
7. Blanke CD. The Eisenberg article reviewed. Oncology 17(11), 1620-1623 (2003).
8. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann. Surg. Oncol. 7(9), 705-712 (2000).
9. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum. Pathol. 32(6), 578-582 (2001).
10. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 3, 655-664 (2002).
11. Nishida T, Hirota S, Taniguchi M et al. Familial gastrointestinal stromal tumors with germline mutation of the KIT gene. Nature Genet. 19, 323-324 (1998).
12. Hirota S, Okazaki T, Kitamura Y. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am. J. Surg. Pathol. 24, 326-327 (2000).
13. Beghini A, Tibiletti M, Roversi G et al. Germline mutation in the juxtamembrane domain of the KIT gene. Cancer 92, 657-662 (2001).
14. Maeyama H, Hidaka E, Ota H et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120, 210-215 (2001).
15. Kinoshita K, Hirota S, Isozaki K et al. Absence of c-kit gene mutations in gastrointestinal stromal tumors from neurofibromatosis Type I patients. J. Pathol. 202, 80-85 (2004).
16. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial recurrence. Mayo Clin. Proc. 74, 543-552 (1999).
17. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580 (1998).
18. Fletcher CDM, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33(6), 459-465 (2002).
19. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GIST): a review. Eur. J. Cancer 38(5), S39-S51 (2002).
20. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology 65, 187-197 (2003).
21. Thomsen L, Robinson TL, Lee JC et al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nature Med. 4, 848-851 (1998).
22. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 152(5), 1259-1269 (1998).
23. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial cells of Cajal. Am. J. Pathol. 154(1), 23-28 (1999).
24. Vanderwinden JM, Rumessen JJ, De Laet MH, Vanderhaeghen JJ, Schiffmann SN. CD34 immunoreactivity and interstitial cells of Cajal in the human and mouse gastrointestinal tract. Cell Tissue Res. 302(2), 145-153 (2000).
25. Miettinen M, El-Rifai W, H L Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum. Pathol. 33(5), 478-483 (2002).
26. Koon N, Schneider-Stock R, Sarlomo-Rikala M et al. Molecular targets for tumour progression in gastrointestinal stromal tumors. Gut 53(2), 235-240 (2004).
27. O'Leary T, Ernst S, Przygodzki R, Emory T, Sobin L. Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab. Invest. 79(12), 1461-1467 (1999).
28. Derre J, Lagace R, Terrier P, Sastre X, Aurias A. Consistent DNA losses on the short arm of chromosome 1 in a series of malignant gastrointestinal stromal tumors. Cancer Genet. Cytogenet. 127(1), 30-32 (2001).
29. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 60(14), 3899-3903 (2000).
30. Takahashi R, Tanaka S, Kitadai Y et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64(3), 266-274 (2003).
31. Gentler T, Schneider-Stock R, Häckel C et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin. Cancer Res. 6, 1811-1818 (2000).
32. Sakurai S, Fukayama M, Kaizaki Y et al. Telomerase activity in gastrointestinal stromal tumors. Cancer 83(10), 2060-2066 (1998).
33. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154(1), 53-60 (1999).
34. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 59(17), 4297-4300 (1999).
35. Lasota J, Wozniak A, Sarlomo-Rikala M et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am. J. Pathol. 157(4), 1091-1095 (2000).
36. Hirota S, Nishida T, Isozaki K et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J. Pathol. 193(4), 505-510 (2001).
37. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn. J. Cancer Res. 92(5), 494-498 (2001).
38. Lasota J, Kopczynski J, Sarlomo-Rikala M et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum. Pathol. 34, 1306-1312 (2003).
39. Lasota J, Dansonka-Mieszkowska A, Stachura T et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod. Pathol. 16, 1257-1264 (2003).
40. Spritz RA, Strunk KM, Lee ST et al. A YAC contig OK spanning a cluster of human Type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 22(2), 431-436 (1994).
41. Weiler SR, Mou S, DeBerry CS et al. JAK2 is associated with the c-kit protooncogene product and is phosphorylated in response to stem cell factor. Blood 87(9), 3688-3693 (1996).
42. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAPK links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. Nature 391(6664), 298-301 (1998).
43. Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L. STAT protein recruitment and activation in c-Kit deletion mutants. J. Biol. Chem. 274(24), 16965-16972 (1999).
44. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3), 925-932 (2000).
45. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol. 33(5), 484-495 (2002).
46. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61(22), 8118-8121 (2001).
47. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am. J. Pathol. 160(5), 1567-1572 (2002).
48. Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 156(3), 791-795 (2000).
49. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708-710 (2003).
50. Allander SV, Nupponen NN, Ringner M et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 61(24), 8624-8628 (2001).
51. Kim NG, Kim JJ, Ahn JY et al. Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int. J. Cancer 85(5), 633-638 (2000).
52. Schneider-Stock R, Boltze C, Lasota J et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J. Clin. Oncol. 21, 1688-1697 (2003).
53. Croom KF, Perry CM. Imatinib mesylate in the treatment of gastrointestinal stromal tumours. Drugs 63(5), 513-522 (2003).
54. Tuveson DA, Willis NA, Jacks T et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20(36), 5054-5058 (2001).
55. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344(14), 1052-1056 (2001).
56. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet 358(9291), 1421-1423 (2001).
57. van Oosterom AT, Judson IR, Verweij J et al. Update of Phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 38(Suppl. 5), S83-S87 (2002).
58. Blanke CD. Therapeutic Options for Gastrointestinal Stromal Tumors. American Society of Clinical Oncology, VA, USA, 266-272 (2003).
59. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002).
60. Blanke C, H Joensuu H, Demetri G et al. Long-term follow-up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Am. Soc. Clin. Oncol. Gastrointest. Cancer Symp. (2004) (Abstract 2).
61. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571, Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer 39(14), 2006-2011 (2003).
62. Heinrich MC, Corless CL, Blande C et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 6).
63. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003).
64. Debiec-Rychter M, Dumez H, Judson I et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on Phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 40, 689-695 (2004).
65. Benjamin RS, Rankin C, Fletcher C et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 3271).
66. Verweij J, Casali PG, Zalcberg J et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomized Phase III trial from the EORTC-STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 3272).
67. van Glabbeke MM, Verweij J, Casali PG et al. Prognostic factors of toxicity and efficacy in patients with gastrointestinal stromal tumors (GIST) treated with imatinib: a study of EORTC-STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 3286).
68. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90(9), 3691-3698 (1997).
69. Le Coutre P, Mologni L, Cleris L et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl Cancer Inst. 91(2), 163-168 (1999).
70. Mahon FX, Deininger MW, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3), 1070-1079 (2000).
71. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001).
72. Fletcher JA, Corless CL, Dimitrijevic S et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 3275).
73. Sommer G, Agosti V, Ehlers I et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc. Natl. Acad. Sci. USA 100(11), 6706-6711 (2003).
74. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97(5), 1413-1421 (2001).
75. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20(6), 1692-1703 (2002).
76. Fiedler W, Mesters R, Tinnefeld H et al. A Phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102(8), 2763-2767 (2003).
77. Desai J, Maki R, Heinrich MC et al. Activity and tolerability of the multitargeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Am. Soc. Clin. Oncol. Gastrointest. Cancer Symp. (2004) (Abstract 7).
78. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 134(4), 656-665 (2003).
79. Hohenberger P, Bauer S, Schneider U et al. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 3288).
80. Casper ES. Gastrointestinal stromal tumors. Curr. Treat. Options Oncol. 1, 267-273 (2000).
81. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231(1), 51-58 (2000).
82. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann. Surg. Oncol. 2(1), 26-31 (1995).
83. Dagher R, Cohen M, Williams G et al. Approval summary-imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8 (10), 3034-3038 (2002).
84. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2(5), 561-566 (1996).
85. Habeck M. FDA licences imatinib mesylate for CML. Lancet Oncol. 3(1), 6 (2002).